- Discovery Reported at the American Association for Cancer Research
(AACR) Annual Meeting -
TORONTO, April 18 /CNW/ - Viventia Biotech Inc., a privately held
biopharmaceutical company advancing a portfolio of novel antibody products
focused on cancer, today announced that it has generated a novel, fully human
anti-cancer antibody, VB1-050, and also identified the novel target for the
antibody, a mutant form of the protein Glut-8. The overexpression of this
target is predominantly associated with the likelihood of disease metastasis
and hence poor patient prognosis. Further research is ongoing to assess the
potential clinical exploitation of VB1-050/Glut-8. These data were presented
at the Annual Meeting of the American Association for Cancer Research (AACR),
which runs from April 14-18, 2007 in Los Angeles, California.
"This work highlights the significant advantages of our discovery
platforms, Hybridomics(TM), ImmunoMine(TM), and UnLock(TM), which not only
generate and characterize novel, fully-human anti-cancer antibodies, but also
can identify their corresponding, often novel, targets," said Dr. Nick Glover,
President and CEO. "As a result, with every research program we have the
potential to generate both a new human antibody with therapeutic potential
and, as importantly a novel high-value cancer drug target, from which a range
of additional drug development strategies can be derived."
Viventia's approach is to leverage the human immune system response to
cancer to generate novel anti-cancer antibodies and identify novel cancer
targets. VB1-050, an IgG MAb, was generated from pooled lymphocytes of cancer
patient samples, using Viventia's Hybridomics(TM) platform. This antibody
demonstrates preferential binding to a host of tumor cell lines, including
breast, liver, prostate and colon, with limited normal tissue reactivity.
Further, internalization of VB1-050 was confirmed by the disappearance of
membrane bound VB1-050 and its appearance inside the cell.
Viventia's proprietary proteomics platform, UnLock(TM), is based upon
two-dimensional liquid chromatography in tandem with LC-MS/MS. Using
UnLock(TM), a mutated version of the Glucose transporter-8/GLUTX1/SLC 2A8 gene
product was identified as the antigen target for VB1-050. This type-II
transmembrane protein belongs to a family of highly related hexose transport
proteins that are distributed in a wide variety of species.
Viventia Biotech retains full global product rights to VB1-050 and has
filed patents on both the antibody and the novel Glut-8 target. The Company is
seeking partners capable of complementing Viventia's development expertise
with their global sales, marketing and commercial capabilities.
About Viventia Biotech:
Viventia Biotech Inc. is a biopharmaceutical company generating a
pipeline of fully human antibodies and identifying novel targets for the
treatment of cancer. Its lead products have been further developed into Armed
Antibodies(TM); powerful and precise anti-cancer drugs that combine cytotoxic
protein payloads with the highly precise tumor-targeting characteristics of
monoclonal antibodies to overcome various forms of cancer. Viventia's lead
product, Proxinium(TM), is undergoing a global Phase III clinical trial -
TARGET - for the treatment of head and neck cancer. Viventia is also
developing Vicinium(TM), which is in a Phase II clinical study for the
treatment of bladder cancer, and VB6-845, beginning a Phase I/II clinical
trial for the treatment of solid tumors. The Company has created a portfolio
of follow-on fully human antibody drug candidates and has a discovery engine
to provide a rich and sustainable long-term pipeline.
For further information:
For further information: James Smith, Tel. (416) 815-0700 x 229, Fax.
(416) 815-0080, Email: email@example.com, www.viventia.com